Lung Cancer Support Group Information Card

Ali Burgin, Advanced Pharmacist at Royal Surrey NHS Foundation Trust (RSCH), has worked with ALK Positive UK charity to design a credit card sized information card containing the specific lung cancer mutation patient support group details.  The card will be given out by pharmacists to patients at RSCH when they receive their first cycle of oral tyrosine kinase inhibitor medication.

 

If any other organisation would like to give this card to their patients please contact Debra Montague (chair of the Oncogene-  Driven Lung Cancer Patient Alliance) via email at [email protected] to receive printed copies (maximum 25 cards per order). Please include the name and full address of the person to receive these cards in the email.

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article